Effectiveness of Prophylactic Oral and/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial

医学 安慰剂 益生菌 内科学 泌尿系统 安慰剂对照研究 抗生素 不利影响 胃肠病学 随机对照试验 临床试验 双盲 微生物学 细菌 病理 生物 替代医学 遗传学
作者
Varsha Gupta,Paola Mastromarino,Ritu Garg
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:78 (5): 1154-1161 被引量:31
标识
DOI:10.1093/cid/ciad766
摘要

Abstract Background Widespread antibiotic resistance has sparked interest in the identification of nonantibiotic strategies, particularly probiotics for the prevention of recurrent urinary tract infections (UTIs). We evaluated the effectiveness of prophylactic probiotic supplementation through oral and intravaginal routes in the prevention of recurrent UTIs. Methods This double-blind, placebo-controlled study enrolled 174 premenopausal women with a history of recurrent UTIs and randomized them to 1 of the 4 treatment groups: placebo (G1, oral placebo + vaginal placebo), oral probiotic (G2, oral lactic acid bacteria and bifidobacteria + vaginal placebo), vaginal probiotic (G3, oral placebo + vaginal lactobacilli), and probiotic combination (oral lactic acid bacteria and bifidobacteria + vaginal lactobacilli), for 4 months. Participants were followed up for symptomatic UTIs for 1 year. The primary end points were the number of symptomatic UTIs at 4 months, the proportion of participants with at least 1 symptomatic UTI, and the time to the first symptomatic UTI. Results The incidence of UTI at 4 months in G1, G2, G3, and G4 was 70.4%, 61.3%, 40.9%, and 31.8%, respectively. The mean number of symptomatic UTI recurrences at 4 months was significantly lower (P < .05) in G3 (1.06) and G4 (1.07) compared with G1 (2.1) and G2 (1.63). Further, the time to first symptomatic UTI (days) was significantly longer (P < .05) in G3 (123.8) and G4 (141.8) compared with G1 (69.3) and G2 (71.9). Probiotic supplementations were well tolerated with no serious adverse events. Conclusions Prophylactic supplementation with either vaginal probiotics or in combination with oral probiotics demonstrated effectiveness in preventing recurrent symptomatic UTI episodes. Clinical Trials Registration Registered at Clinical Trials Registry India (CTRI): CTRI/2014/02/004425 (https://ctri.nic.in).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一棵草发布了新的文献求助10
刚刚
爆米花应助Bigwang采纳,获得10
1秒前
3秒前
情怀应助钰泠采纳,获得10
3秒前
科研通AI6.2应助李悟尔采纳,获得10
4秒前
科研通AI2S应助火星上手机采纳,获得10
4秒前
4秒前
魏然完成签到,获得积分10
5秒前
醉熏的惜芹完成签到 ,获得积分20
5秒前
雨庵完成签到,获得积分10
6秒前
7秒前
问霖完成签到,获得积分10
8秒前
铁豆完成签到,获得积分10
8秒前
GS发布了新的文献求助10
11秒前
11秒前
Mark应助wang采纳,获得10
12秒前
13秒前
赘婿应助霂梣采纳,获得10
13秒前
脑洞疼应助lyd采纳,获得10
13秒前
15秒前
今后应助超级幻梅采纳,获得10
16秒前
完美世界应助kim采纳,获得10
17秒前
赘婿应助ggy采纳,获得10
18秒前
tyj发布了新的文献求助10
19秒前
大胆的微笑完成签到 ,获得积分10
19秒前
vicco426发布了新的文献求助10
19秒前
souvenir完成签到,获得积分10
20秒前
21秒前
阳光紫南发布了新的文献求助10
21秒前
筱筱发布了新的文献求助10
21秒前
李健的小迷弟应助小琼琼采纳,获得10
22秒前
23秒前
苏小猫完成签到,获得积分10
23秒前
24秒前
24秒前
24秒前
Ding完成签到,获得积分10
25秒前
MutantKitten发布了新的文献求助10
27秒前
kingwill发布了新的文献求助30
28秒前
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
卤化钙钛矿人工突触的研究 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Malcolm Fraser : a biography 700
Handbook of Optical Systems,Volume 6:Advanced Physical Optics 666
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6514839
求助须知:如何正确求助?哪些是违规求助? 8308202
关于积分的说明 17755138
捐赠科研通 5616636
什么是DOI,文献DOI怎么找? 2924781
邀请新用户注册赠送积分活动 1901810
关于科研通互助平台的介绍 1763137